A Multicenter, Single-blind, Randomized, Controlled Study of the Safety and Effectiveness of VYC-25L Hyaluronic Acid Injectable Gel for Restoration and Creation of Facial Volume in the Chin and Jaw - V25L-001

Allergan0 个研究点目标入组 24 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

阶段: 不适用
状态: 尚未招募
发起方: Allergan
入组人数: 24

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 99（—）

入选标准

•1. 18 years of age or older and in good general health
•2. Has chin retrusion (G-Sn-Pog angle of 145° to 165°) based on calculations of facial angle derived from digital images obtained using Canfield imaging equipment and software
•3. Investigator considers the subject*s chin/jaw retrusion to be amenable to correction
•with a treatment goal consistent with increasing chin projection horizontally (in the profile view)
•4. Ability to follow study instructions and likely to complete all required visits
•5. Written informed consent has been obtained

排除标准

•1. Has clinically significant malocclusion and/or macrogenia (ie, Class I [macrogenia: excess in the vertical or horizontal dimension or excess in both dimensions], Class III [combined macrogenia and microgenia: excess in one dimension with deficiency in the other], or Class VI [pseudomacrogenia: excess soft tissue over a normal skeleton]) in the investigator*s judgment
•2. Has ever received permanent facial implants (eg, polymethylmethacrylate, silicone, polytetrafluoroethylene) anywhere in the face or neck, or is planning to be implanted with any of these products during the study
•3. Has tattoos, piercings, facial hair (ie, beard, mustache), or scars below and including the subnasale that would interfere with visual assessment of the chin, jowls, or jawline
•4. Has dentures or any device covering all or part of the palate or is planning to undergo any dental procedure (other than prophylaxis and dental fillings) during the study
•5. Has undergone semipermanent dermal filler treatment (eg, calcium hydroxyapatite, poly-L-lactic acid) in the chin or jaw area within 36 months before enrollment or is planning to undergo such treatment during the study
•6.Has undergone dermal filler injections or fat injections, or has undergone any surgery in the chin or jaw area (including marionette lines, pre-jowl sulci, mandibular body, or masseter muscles) within 24 months before enrollment or is planning to undergo any of these procedures during the study
•7. Has undergone dermal filler injections in the glabellar area or nose within 12 months before enrollment or is planning to undergo such treatment within the first 3 months after study treatment
•8. Has undergone mesotherapy or cosmetic resurfacing (laser, photomodulation, intense pulsed light, radio frequency, dermabrasion, moderate or greater depth chemical peel, or other ablative procedures) anywhere in the face or neck or botulinum toxin injections below the subnasale (including injections to the masseter muscles) within 6 months before enrollment or is planning to undergo any of these procedures during the study
•9. Has experienced trauma to the chin and jaw area within 6 months before enrollment or has residual deficiencies, deformities, or scarring
•10.Has, in the opinion of the investigator, significant skin laxity in the chin, jaw, or neck
•11.Has a tendency to develop hypertrophic scarring
•12. Has been previously diagnosed with streptococcal disease (eg, recurrent sore throat, acute rheumatic fever)
•13.Has a history of anaphylaxis or allergy to lidocaine (or any amide-based anesthetics), hyaluronic acid products, or Streptococcal protein, or is planning to undergo desensitization therapy during the term of the study
•14.Has porphyria or untreated epilepsy
•15.Has active autoimmune disease
•16.Has current cutaneous or mucosal inflammatory or infectious processes (eg, acne, herpes, gum disease), abscess, an unhealed wound, or a cancerous or pre-cancerous lesion below the subnasale (Study device injection may be delayed for subjects with a history of recurrent oral herpes lesions who take prophylactic doses of antiviral/herpes medication for at least 2 days before study treatment administration.)
•17.Is on a concurrent regimen of lidocaine or structurally-related local anesthetics (eg, bupivacaine); is on a concurrent regimen of drugs that reduce or inhibit hepatic metabolism (eg, cimetidine, beta blockers)
•18.Has impaired cardiac c

研究者

发起方

Allergan

相似试验

招募中

1 期

A Multicenter, Randomized, Double-blind, Controlled trial of effects of using intravenous metoclopramide to increase mucosal visualization during endoscopy in patients with acute upper gastrointestinal bleedingOut-patient present in emergency department or in-patient has new inset upper gastrointestinal bleeding and received endoscopy within 24 hours of presentation or visited hospitalUGIB, UGIH, gastrointestinal hemorrhage, gastrointestinal bleeding, endoscopy, hematemesis, GI bleeding

TCTR20210708004avamindradhiraj university Research Fund300

已完成

不适用

A multicentre, single blinded, randomized controlled trial on the (cost) effectiveness of a prevention course on reducing or preventing disabilities from musculoskeletal complaints in music students at Dutch conservatories.

NL-OMON37325niversiteit Maastricht170

进行中（未招募）

1 期

M7824 with cCRT in Unresectable Stage III NSCLCnresectable Stage III Non-small Cell Lung CancerMedDRA version: 20.0Level: PTClassification code 10029519Term: Non-small cell lung cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2018-003265-34-ESMerck KGaA350

进行中（未招募）

1 期

M7824 with cCRT in Unresectable Stage III NSCLCnresectable Stage III Non-small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10029519Term: Non-small cell lung cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2018-003265-34-DEMerck KGaA160

进行中（未招募）

1 期

EUCTR2018-003265-34-HUMerck KGaA160